射血分数保留的心力衰竭患者年龄相关特征与结局
本研究基于TOPCAT、I-PRESERVE和CHARM Preserved三项大型HFpEF试验中左室射血分数≥45%的患者数据,按年龄分组比较临床特征与结局。结果显示年轻患者(≤55岁)更多为肥胖非白人男性且生活质量更差,猝死比例更高;老年患者(≥85岁)合并症更多且死亡率更高,非心血管死亡更常见。
要点
- 年轻HFpEF患者(≤55岁)更多为肥胖非白人男性,生活质量更差。
- 年轻患者死亡以心血管原因为主,猝死比例最高。
- 老年患者(≥85岁)合并症多,死亡率高,非心血管死亡更常见。
核心结论
- 与老年患者相比,年轻HFpEF患者较少为白人、更多为肥胖男性,且更常死于心血管原因尤其是猝死。
- 老年HFpEF患者合并症更多,更常死于非心血管原因。
研究设计与样本
- 基于TOPCAT、I-PRESERVE和CHARM Preserved三项大型HFpEF试验中左室射血分数≥45%的患者数据。
- 按年龄分为≤55岁(n=522)、56-64岁(n=1,679)、65-74岁(n=3,405)、75-84岁(n=2,464)和≥85岁(n=398)五组。
- 比较各组临床与超声心动图特征、死亡率和住院率、死亡模式及生活质量。
主要发现
- 年轻患者(≤55岁)更多为肥胖、非白人男性;老年患者更多为白人女性,房颤、高血压和慢性肾病(eGFR<60 ml/min/1.73 m2)患病率更高。
- 尽管合并症较少,年轻患者生活质量较老年患者(≥85岁)更差。
- 与≤55岁患者相比,≥85岁患者死亡率更高(HR 6.9;95%CI 4.2-11.4)。
- 在死亡患者中,≤55岁患者猝死比例最高(p<0.001);≥85岁患者非心血管死亡更常见(34% vs 20%;p<0.001)。
临床怎么用
- 对年轻HFpEF患者应关注肥胖等代谢因素及猝死风险。
- 对老年HFpEF患者应综合管理多重合并症及非心血管死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although heart failure with preserved ejection fraction (HFpEF) is considered a disease of the elderly, younger patients are not spared from this syndrome. OBJECTIVES: This study therefore investigated the associations among age, clinical characteristics, and outcomes in patients with HFpEF. METHODS: Using data on patients with left ventricular ejection fraction ≥45% from 3 large HFpEF trials (TOPCAT [Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function], I-PRESERVE [Irbesartan in Heart Failure With Preserved Systolic Function], and CHARM Preserved [Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity]), patients were categorized according to age: ≤55 years (n = 522), 56 to 64 years (n = 1,679), 65 to 74 years (n = 3,405), 75 to 84 years (n = 2,464), and ≥85 years (n = 398). This study compared clinical and echocardiographic characteristics, as well as mortality and hospitalization rates, mode of death, and quality of life across age categories. RESULTS: Younger patients (age ≤55 years) with HFpEF were more often obese, nonwhite men, whereas older patients with HFpEF were more often white women with a higher prevalence of atrial fibrillation, hypertension, and chronic kidney disease (eGFR <60 ml/min/1.73 m2). Despite fewer comorbidities, younger patients had worse quality of life compared with older patients (age ≥85 years). Compared with patients age ≤55 years, patients age ≥85 years had higher mortality (hazard ratio: 6.9; 95% confidence interval: 4.2 to 11.4). However, among patients who died, sudden death was, proportionally, the most common mode of death (p < 0.001) in patients age ≤55 years. In contrast, older patients (age ≥85 years) died more often from noncardiovascular causes (34% vs. 20% in patients age ≤55 years; p < 0.001). CONCLUSIONS: Compared with the elderly, younger patients with HFpEF were less likely to be white, were more frequently obese men, and died more often of cardiovascular causes, particularly sudden death. In contrast, elderly patients with HFpEF had more comorbidities and died more often from noncardiovascular causes. (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function [TOPCAT]; NCT00094302; Irbesartan in Heart Failure With Preserved Systolic Function [I-PRESERVE]; NCT00095238; Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM Preserved]; NCT00634712).
引用
- Tromp J, Shen L, Jhund PS, et al. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019. PMID: 31370950. doi:10.1016/j.jacc.2019.05.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。